Colorectal cancer is the second commonest cause of cancer death in the UK. An effective national screening programme is urgently required to reduce the substantial morbidity and mortality from the disease. 
Abstract
Colorectal cancer is the second commonest cause of cancer death in the UK. An effective national screening programme is urgently required to reduce the substantial morbidity and mortality from the disease. The success of any screening programme will depend on the screening test detecting early Dukes's A carcinomas and adenomatous polyps. Prognosis is directly related to tumour staging and a proportion of carcinomas are thought to arise from polyps. Two screening methods exist -faecal occult blood testing and sigmoidoscopy. Large trials of faecal occult blood testing show that it detects more early lesions than in patients presenting with symptoms, but whether this reduces mortality is not yet confirmed and lack of sensitivity for cancers and polyps may ultimately limits its usefulness. The role of sigmoidoscopy in screening, particularly flexible sigmoidoscopy, has not been fully investigated. Flexible sigmoidoscopy has a greater sensitivity for distal lesions than stool testing and a randomised controlled trial of its efficacy is planned in Britain. Compliance with screening is essential to ensure its cost effectiveness in both health and economic terms. Large trials of faecal occult blood testing conducted over several years achieved compliance rates in excess of 60%/ although in smaller studies these are often much less. Women frequently participate more than men. There are many reasons for noncompliance including lack of appreciation ofthe concept ofasymptomatic illness and fear of the screening tests and cancer itself. Colorectal cancer screening is relatively cheap compared with breast and cervical cancer screening. Provisional cost estimates suggest that the amount spent to detect or prevent cancer by screening is similar to the amount required to treat a symptomatic patient. (Gut 1995; 36: 590-598) For screening to be effective five essential criteria must be met. Firstly, the disease in question should be an important public health problem causing substantial morbidity and mortality. Colorectal cancer is the second commonest cause of cancer death in Britain, with a similar high mortality in the USA of 57 000 annual fatalities. The second criterion is that the disease's natural history should be compatible with early detection at a premalignant or asymptomatic stage. Colorectal cancers are thought to arise from benign adenomas so screening must detect these premalignant lesions. Screening must also diagnose cancer at an early stage as prognosis is related to Dukes's staging. Thirdly, the screening test must be sensitive, safe, and exclude those who do not have the disease. The current methods used in colorectal cancer screening programmes are stool tests to detect occult blood from tumours and sigmoidoscopy to visualise distal lesions. The fourth criterion is high compliance with the screening test. Compliance with screening is related to the method of delivery. A thorough understanding of why people fail to participate is critical to increase uptake in future programmes. Finally, the cost of screening must be comparable to the money saved by preventing the disease. This review discusses whether these criteria are met in colorectal cancer screening and compares current knowledge with what is known in cervical and breast cancer screening. The crucial question is whether early detection of disease reduces mortality. Screening may just detect cancer earlier in those who are going to succumb to the disease anyway (lead-time bias) or detect slow growing, well differentiated tumours with a good prognosis (length bias). This length bias has been reported15 where more screen detected cancers (90%) were well or moderately differentiated compared with controls (70%). The Minnesota study is the first to report a significant mortality reduction with annual faecal occult blood testing,17 but not in those tested once every two years. In the annually screened group the 13 year cumulative mortality fell by 33%. This result must be interpreted cautiously as nearly 10% of slides were positive and 38% of participants had at least one colonoscopy. Reduction in deaths may be due to cancers and polyps detected by colonoscopy rather than as a benefit of stool testing. The New York'9 study reported a 43% reduction in mortality from colorectal cancer, although this just failed to reach statistical significance (p=0.053, one sided). Provisional results from the first five years of the Danish programme did not show a mortality reduction with two yearly screening. The full results of the European trials of faecal occult blood testing should be available in several years.
A case-control study from population based screening in Saarland, Germany showed a benefit from faecal occult blood testing in women but not in men. 22 Faecal occult blood testing is offered as an optional component of the insurance system in Germany. For three years before diagnosis, 13% of male subjects and 14% of male controls had at least one symptomatic faecal occult blood test. For women, 16% of subjects had been screened and 29% of controls. Clearly many selection biases exist and these results must be interpreted as supportive of the benefits of screening.
Despite the need for clinical trials to show the benefits of screening, this only exists for breast cancer. Mammographic screening for breast cancer reduces mortality by 30%, although this is confined to women over the age of 50 years. The non-randomised UK trial showed a reduction in mortality of 20%, although this just failed to reach significance.
There is no randomised trial of cervical screening, but supportive evidence comes from a comparison of screened and unscreened groups and correlations between mortality reduction and intensity of screening. For example, time trends in mortality from cervical cancer have been compared in Nordic countries and correlated with the intensity of screening programmes. In Iceland, where the nationwide programme had the widest target age range, the fall in mortality was greatest at 80%.
THE PROBLEM OF 'MISSED' CANCERS
Missed cancers give screening programmes a poor reputation. The interval cancer rate is the number presenting between a negative test and rescreening divided by the total number of cancers diagnosed. This rate assumes missed tumours were present at the time of testing, although this may not be so. In Nottingham and Denmark there were interval cancer rates of 28% and 48% respectively. 16 Much of sigmoidoscopy's value is thought due to the protective effect of the first sigmoidoscopy which diagnoses and removes polyps27 and enters people into colonic surveillance programmes. Atkin et a127 argued that such a programme could prevent 5500 colorectal cancer cases and 3500 deaths in the UK each year, but this is dependent on a compliance of 65%.
UNCONTROLLED TRIALS OF SIGMOIDOSCOPY
In an uncontrolled study in 21 000 people, 1 13 800 rigid sigmoidoscopies were performed together with polypectomy where indicated. 28 Twenty seven cancers were found on initial examination -that is, one in every 800 people screened. The follow up period was of over 100 000 patient years experience. Only 13 rectal cancers developed compared with an expected 90 and the authors concluded that distal polyp removal led to an 85% reduction in incidence of rectal cancer. The five year survival rate of 64% was twice that reported for people who present with colonic symptoms. There were 27 cancers detected at the initial screening examination. If these were added to the 13 detected by follow up examination, the risk of cancer was reduced by only a half. In the published trials compliance has been highest in the USA (Table I) where volunteers from the American Cancer Society17 and those in private health schemes were recruited.18
European studies are community based programmes and in Scandinavia202' compliance reached 65%. In Nottingham compliance rose from an initial 45% to 60% in the most recently recruited practices. '6 Compliance is generally better in women aged 50 to 60 years. Smaller studies from general practice confirm this sex and age difference. In Frome, Somerset, overall compliance was only 27%, and in both sexes compliance was least in those over 70 years old. Similarly in Salford, Manchester, overall participation was 28% with more 40 to 49 year olds completing kits (31%) than those over 70 (17%). In Surrey, the compliance rate was 42%, and again more young women participated. However, there is still a long way to go to achieve uptake comparable to the 60% seen in British trials of mammography.
The effect of social class on the uptake of stool testing is uncertain. Farrands et a135 found acceptance lowest in social classes 3 and 4. In contrast, Dent and Goulston36 reported that blue collar workers said they were more likely to participate (78%) than white collar staff (65%). In mammography and smear testing it is least in lower social classes.
METHODS OF DELIVERING AND PROMOTING SCREENING
The method of delivery affects compliance with screening. A letter of invitation from a family doctor was more effective than a similar letter from a university department of community medicine. 37 In Chicago, promotion of screening on the television's evening news was reinforced by radio and newspaper features. Of 54 000 kits distributed, only 14 000 (26%) were completed. Similarly in Pennsylvania, an educational series on colorectal cancer was delivered nightly by a local television station. A total of 130 000 tests were delivered as a result of the programmes and 53% returned.
Administrative problems encountered in cervical screening provide lessons for colorectal cancer programmes. Frequently invitations are sent to the wrong address or to women who have had smears of even a hysterectomy. These problems are largely due to patients failure to notify general practitioners of address changes and practices not informing family practitioner committees. In a study of non-attendance at mammography, 14% of alleged non-compliers had actually attended for screening. Other interventions used in cervical and breast screening including specific appointment times for screening, educational pamphlets at routine consultations, and tagging the case notes of non-compliers also have a place in colorectal screening.
ACCEPTABILITY OF STOOL TESTING
Non-compliance studies are hard because people who decline screening are reluctant to be interviewed and it can be difficult to elicit precise reasons and be confident they are valid. In Denmark where 1000 non-compliers were questioned, 37% did not give a specific reason43 and in a British group,35 40%/o were 'too busy' and 'didn't get round to it'. In a study of hospital employees reasons given were 'too lazy, couldn't be bothered, kept putting it off, forgot or mislaid slides'. Such apparent lethargy and lack of time may mask real fears about screening and cancer. In a questionnaire study, Macrae et al reported that refusers were more likely to rate tests as embarrassing, distasteful, worrisome, discomforting, or inconvenient than acceptors.44 Farrands et a135 found that 22% of non-compliers thought faecal testing unacceptable, although this was not investigated further. In a workplace programme45 a third of those who received a kit described it as unpleasant and 17% said the specimen was too difficult to collect. As less than 50% of people returned a questionnaire the number who held this view was probably higher. Finally, in a general practice based study, non-completers were seven times more likely to rate faecal occult blood testing as 'disgusting' than completers.46 Designing a more acceptable kit may increase compliance but is a difficult task. One system under evaluation involves dropping a card into the toilet and looking for a colour change.46 This relies on blood on the surface of the stool forming a film with which the test card reacts. It is preferred by patients because samples do not have to be collected. Unfortunately it is less sensitive than the Haemoccult test and problems may occur when patients read their own tests. In another test, participants wipe their anus after defecation and then develop the smear with a guiac/peroxide spray.46
The immediate barriers to completing a screening test seem to outweigh the possible long term benefits of screening in some noncompliers. This is true in cervical cancer screening where a major concern is that taking the smear will be painful and embarrassing. Similarly, in breast cancer screening many women are concerned about the clinic experience where over a third expressed negative feelings and a dislike of physical examination, doctors, and the presence of other women at the clinic.
THE CONCEPT OF ASYMPTOMATIC ILLNESS
Concepts of asymptomatic illness and screening need to be promoted as the public are unaware of these.35 43 45 Farrands et al found acceptors were more aware that cancer could be present before causing symptoms and could be diagnosed by medical tests. 35 Acceptors were more likely to believe that asymptomatic cancer was curable. Similarly, Silman et al found that 64% of those who declined screening did so because of lack of symptoms,45 and in Denmark43 13% refused because they felt well. Similarly, in cervical screening attenders were more likely than non-attenders to believe that smears can reveal disease before symptoms and that early detection is beneficial. In mammography, many non-attenders thought screening unnecessary as they were well and that they should not waste professionals' time.
Other reported reasons for non-participation include intercurrent illness, advancing age,43 and fear of cancer.35 45 Klaaborg et a143 found that 32% of rejectors cited another illness or current medical treatment and 4% felt they were too old to benefit. In two British studies35 45 Cost was more dependent on clinical variables such as test sensitivity and compliance than on staff and administrative resources. A similar sum was spent on investigations and treatment following a positive stool test as for a symptomatic patient. Although it is more expensive than a barium enema, colonoscopy is the investigation of choice as it has a greater sensitivity for polyps.
The cheapest method of screening was to mail kits from a hospital unit rather than asking individuals to collect them as this produces higher compliance. Screening older asymptomatic people is more cost effective as the incidence of disease is increased. The price per cancer detected at initial and the subsequent rescreen is similar, but rises considerably for the second rescreen at four years, as fewer people with an abnormality are found. The evidence shows that colorectal cancer screening satisfies many of the criteria for screening programmes. The disease is common and can be diagnosed early in its natural history when treatment is easiest and prognosis best. Although faecal occult blood tests are cheap and non-invasive they lack sensitivity so the value of other tests such as sigmoidoscopy needs to be determined. The available evidence shows that the costs of a screening programme are of the same order of magnitude as the cost of treatment. The calculated cost is less than that required in breast and cervical screening programmes. Currently compliance with colorectal cancer screening is a major deterrent to government investment. To address this problem more research is needed on methods of delivery and reasons why people decline tests.
Our ultimate aim should be an effective national screening programme which will alleviate morbidity and mortality caused by colorectal cancer. While evaluating methods of screening is vital, equal emphasis must be placed on improved public understanding and acceptance of the process.
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